Literature DB >> 32410979

Freezing of Speech Single Questionnaire as a Screening Tool for Cognitive Dysfunction in Patients With Dementia With Lewy Bodies.

Pai-Yi Chiu1, Guang-Uei Hung2, Cheng-Yu Wei3, Ray-Chang Tzeng4, Ming-Chyi Pai5,6,7.   

Abstract

INTRODUCTION: Freezing phenomenon is a striking feature of Parkinson's disease. However, it has never been studied in people with dementia with Lewy bodies (DLB). We designed a freezing of speech single questionnaire (FOSSQ) and investigated the frequency and association of freezing of speech (FOS) in patients with DLB and other types of dementia.
METHODS: This is a retrospective analysis of data from the project of history-based artificial intelligent computerized dementia diagnostic system. We compared the frequencies of FOS among non-demented (ND) participants, patients with Alzheimer's disease (AD), vascular dementia (VaD), and DLB. Further, we explored the association factors of FOS in all the participants.
RESULTS: We enrolled 666 individuals with the following disease distribution: 190, ND; 230, AD; 183, VaD; and 63, DLB. Compared to individuals with ND (2.1%), patients with AD (6.1%), or VaD (18.0%), DLB (54.0%) showed a significantly higher frequency of positive FOS (all p < 0.001). The association factors of FOS were older age, more severe dementia, more severe motor dysfunction, fluctuating cognition, visual hallucinations, parkinsonism, rapid eye movement sleep behavior disorder, attention, mental manipulation, and language.
CONCLUSION: Our study showed that the informant-based FOSSQ may be a practical screening tool for discriminating DLB from individuals with ND or other forms of dementia. The FOSSQ can be applied in clinical practice as well as on the artificial intelligent platform.
Copyright © 2020 Chiu, Hung, Wei, Tzeng and Pai.

Entities:  

Keywords:  Alzheimer’s disease; dementia with Lewy bodies; fluctuating cognition; freezing of speech; vascular dementia

Year:  2020        PMID: 32410979      PMCID: PMC7199820          DOI: 10.3389/fnagi.2020.00065

Source DB:  PubMed          Journal:  Front Aging Neurosci        ISSN: 1663-4365            Impact factor:   5.750


Introduction

Freezing phenomenon is a striking feature of Parkinson’s disease (PD). Freezing of gait (FOG) is a form of akinesia and is one of the most disabling symptoms of PD (Giladi et al., 2001). Previous studies on FOG in PD have reported a prevalence of 7.1–46% (Giladi et al., 2001; Macht et al., 2007) according to different criteria. However, there have only been a few studies on the freezing of speech (FOS) phenomenon (Ackermann et al., 1993; Giladi et al., 1997; Louis et al., 2001; Park et al., 2014; Vercruysse et al., 2014) in PD. Further, freezing phenomenon has rarely been mentioned or studied in neurological disorders other than PD, with some mentioning the phenomenon of FOS sharing a similar neural mechanism with FOG (Park et al., 2014; Vercruysse et al., 2014). The underlying mechanism of the freezing phenomenon is probably related to dysfunction of the fronto-striatal circuits (Vercruysse et al., 2014). To our knowledge, there have been no studies on FOS in dementia with Lewy bodies (DLB) or other degenerative types of dementia. DLB is one of the Lewy body diseases (LBD) and it shares a similar pathological manifestation with PD, especially PD with dementia (PDD) (Kosaka et al., 1984; Jellinger, 2018). Therefore, patients with DLB should demonstrate similar freezing phenomenon as PD/PDD. It remains unclear whether FOS is a deficit of language or other cognitive functions. However, language dysfunction is indeed one of the common cognitive features of a diagnosis of dementia due to Alzheimer’s disease (AD) or other forms of dementia (McKeith et al., 2005; McKhann et al., 2011; Hardy et al., 2016). Similarly, the association factors of FOS have not yet been well studied. To study FOS, we designed a simple informant-based FOS single questionnaire (FOSSQ) that was embedded in the History-based Artificial Intelligent Clinical Dementia Diagnostic System (HAICDDS) (Lin et al., 2018; Chiu et al., 2019). We aimed to investigate the frequency and association of FOS in DLB and other types of dementia. We proposed that since the FOS phenomenon is a striking feature of PD, it could be an important feature of DLB because both language (Lin et al., 2018) and motor deficits (McKeith et al., 2005) are common clinical presentations of DLB. Based on the findings that the underlying mechanism of the freezing phenomenon is probably related to dysfunction of the fronto-striatal circuits (Vercruysse et al., 2014), we proposed that FOS could be a deficit involving language and motor dysfunction as well as dysfunction of other cognitive functions such as attention and executive dysfunction. Similarly, as a striking clinical phenomenon, we also proposed that FOS may involve fluctuation of attention and cognition, and thus performed fluctuation scale comparisons.

Materials and Methods

This is a sub-study of the project of HAICDDS, which is currently used as a registration platform in the Show Chwan Healthcare System (Lin et al., 2018; Chiu et al., 2019). Participants who visited either hospital of the healthcare system with suspected cognitive or motor dysfunction were registered with their demographical, clinical, cognitive, neuropsychiatric, motor, laboratory, and neuroimaging data in the database. The HAICDDS questionnaire is part of the database for recording of clinical history. It is composed of 100 questions designed after a consensus meeting of 12 neurologists, one geriatric psychiatrist, three nuclear medicine doctors, and one neuroradiologist. The fundamental structure of the questionnaire is similar to that of history-taking used by physicians for acquiring detailed clinical information. Before commencing the project, thirty patients with their informants were assessed by neuropsychologists from three centers and the reproducibility was studied using the interrater reliability analysis. Cronbach’s alpha coefficient was calculated to estimate the reliability of the entire novel screening questionnaire. The original writing of FOSSQ was in Chinese as follows: 跟人講話時常常思緒突然中斷,腦袋好像一片空白,難以互動嗎 (The tentative translation to English is: “When speaking, does he/she pause frequently, seem blank, and have trouble communicating?”). In this sub-study, we analyzed and compared the FOSSQ results among non-demented (ND) participants as well as participants with AD, vascular dementia (VaD), and DLB. Further, we studied the association factors of FOS among the participants.

Diagnosis of AD, VaD, or DLB

A diagnosis of AD was made according to the criteria for dementia due to AD developed by the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for AD (McKhann et al., 2011). A diagnosis of VaD was made according to the criteria for probable VaD or possible VaD in the 2011 AHA/ASA criteria for vascular cognitive impairment (VCI) (Gorelick et al., 2011). A diagnosis of DLB was made according to the revised consensus criteria for probable DLB developed by the fourth report of the DLB consortium (McKeith et al., 2017).

Diagnosis of ND, or Different Stages of Dementia

ND participant was diagnosed with a global CDR (Morris, 1993) score of 0 or 0.5 without significantly impaired activities of daily living, which was defined by an Instrumental Activities of Daily Living (IADL) score greater than 6 (Mao et al., 2018). A diagnosis of dementia was made according to the criteria for dementia developed by the NIA-AA (McKhann et al., 2011). Specifically, people with dementia had impairments in two cognitive domains or more as well as declined daily functions (at least one of the domains of community affairs, home hobbies, and personal care with a CDR score ≥ 0.5 and an IADL score ≤ 6) (Mao et al., 2018). Dementia severity was defined by the global CDR scale score; specifically, participants with a global CDR score of 0.5, 1, 2, and 3 were defined as having very mild, mild, moderate, and severe dementia, respectively (Morris, 1993).

Procedure of the Study

This is a retrospective analysis of data from the HAICDDS, which is currently applied in three centers in Taiwan (two in central Taiwan and one in southern Taiwan). Daily function was assessed using the Instrumental Activities of Daily Living (IADL) Scale (Lawton and Brody, 1969). Cognitive function was assessed using the Cognitive Abilities Screening Instrument (CASI) (Lin et al., 2002) and the Montreal Cognitive Assessment (MoCA) (Chen et al., 2016). Neuropsychiatric symptoms were assessed using the Neuropsychiatric Inventory (NPI) (Cummings, 1988). Language function was assessed using the language subscales in the CASI and HAICDDS (HAICDDS-Language) (Lin et al., 2018). Language domain in CASI screens cognitive performance on reading, writing, naming, and comprehension whereas, language questions in HAICDDS acquire information on speech fluency, comprehension, naming, volume, and tone based on clinical history (Lin et al., 2018). Trained neuropsychologists administered the cognitive tests and NPI to all the patients.

Statistics

The Chinese version of SPSS 22.0 for Windows (IBM, SPSS Inc., Chicago) was used for statistical analyses. Between-group comparisons of demographic data, neuropsychological tests, CDR sum of boxes (CDR-SB), IADL score, MoCA score, CASI score, NPI total score (NPI-sum), motor subscale of the Unified Parkinson’s Disease Rating Scale (UPDRS-M), and DLB features were analyzed using independent t-test or one-way ANOVA with either Bonferroni or Dunnett T3 post hoc analysis according to the homogeneity of variance. Between-group comparisons of demographic and background characteristics with positive FOSSQ (FOSSQ +) and negative FOSSQ (FOSSQ-) were adjusted for age and disease severity. Comparisons of each cognitive domain in the CASI between FOSSQ + and FOSSQ- groups were adjusted for age, gender, and disease severity. Comparison of frequency of symptom fluctuation in the Mayo Fluctuation Composite Score (MFCS) and language symptoms in the HAICDDS-Language between FOSSQ + and FOSSQ- groups were adjusted for age and disease severity.

Ethical Consideration

The participants were selected from a registry-based database of the Show Chwan Health System. The study design was retrospective, and the data were anonymously analyzed. The Committee for Medical Research Ethics of Show Chwan Memorial Hospital reviewed the project and the Data Inspectorate approved the study.

Results

We enrolled 666 individuals with the following disease distribution: 190, ND; 230, AD; 183, VaD; and 63, DLB. The frequency of FOSSQ + in patients with CDR scores of 0, 0.5, 1, 2, and 3 were 3.8, 3.0, 15.2, 26.1, and 43.5%, respectively. Compared to patients with ND (2.1%), AD (6.1%), or VaD (18.0%), those with DLB (54.0%) showed a significantly higher frequency of FOSSQ + (all p < 0.001). Comparison of demographic and background characteristics among patients with ND, AD, VaD, and DLB revealed significant differences in all the parameters (p < 0.001), except for informant age or education (Table 1).
TABLE 1

Comparison of demographic data among ND, AD, VaD, and DLB groups.

GroupsNDADVaDDLBF/x2p
N19023018363
Age, year68.1 ± 11.480.1 ± 8.673.7 ± 10.780.8 ± 7.057.24<0.001
Female, N (%)100 (52.6)154 (67.0)77 (42.1)36 (57.1)29.19<0.001
Education, year7.4 ± 4.94.4 ± 4.56.0 ± 4.85.3 ± 13.09.15<0.001
CDR, 0/0.5/1/2/353/137/0/0/00/85/77/51/170/66/52/48/170/9/22/20/12324.18<0.001
CDR-SB0.7 ± 0.76.7 ± 4.47.2 ± 5.09.7 ± 5.2128.61<0.001
IADL7.7 ± 0.62.7 ± 2.72.6 ± 2.91.4 ± 2.3235.16<0.001
MoCA20.0 ± 6.07.4 ± 5.59.1 ± 6.87.1 ± 6.5175.02<0.001
CASI81.5 ± 12.144.8 ± 21.547.8 ± 24.643.2 ± 23.3139.26<0.001
NPI-sum3.4 ± 5.05.2 ± 6.98.3 ± 9.315.6 ± 14.031.02<0.001
UPDRS-M7.1 ± 7.111.4 ± 12.030.6 ± 14.628.9 ± 11.137.76<0.001
DLB features, N (%)
Fluctuation4 (2.1)32 (13.9)48 (26.2)32 (50.8)91.61<0.001
VH1 (0.5)10 (4.3)16 (8.7)29 (46.0)136.07<0.001
Parkinsonism32 (16.8)42 (18.3)73 (39.9)59 (93.7)157.39<0.001
RBD17 (8.9)13 (5.7)13 (7.1)34 (54.0)123.49<0.001
DaTabN2 (6.9)3 (20.0)8 (47.1)19 (79.2)31.94<0.001
Informant
Age, year58.8 ± 13.354.9 ± 14.355.7 ± 13.754.3 ± 13.71.960.120
Education, year11.1 ± 7.511.1 ± 4.310.2 ± 4.811.1 ± 4.90.600.613
Comparison of demographic data among ND, AD, VaD, and DLB groups. Comparison of demographic and background characteristics between the FOSSQ + and FOSSQ- groups before adjustment revealed that the FOSSQ + group had a significantly older age and more severe dementia stages. Further, there were significant differences in all other parameters (p < 0.001) except for gender, education, and history of cerebrovascular accident (Table 2). After adjustment for age and disease severity, FOSSQ + had more males and higher DLB features including UPDRS-M, cognitive fluctuations, visual hallucinations, parkinsonism, and REM sleep behavior disorder (Table 2).
TABLE 2

Comparison of demographic and background characteristics between groups with FOSSQ + and FOSSQ – adjusted for age and disease severity according to CDR.

Mean ± SD
Non-adjusted
Adjusted
FOSSQ +FOSSQ−t/χ2pOR (95% CI)p
N85581
Age, years77.3 ± 10.174.6 ± 11.32.200.028NA
CDR, 0/0.5/1/2/32/9/23/31/2051/288/128/88/2687.79<0.001NA
Female, N (%)39 (45.9)328 (56.3)3.35NS0.56 (0.34–0.92)0.023
Education, years5.7 ± 11.35.8 ± 4.9−0.14NS1.01 (0.98–1.05)NS
IADL1.4 ± 2.44.3 ± 3.3−7.97<0.0010.95 (0.77–1.16)NS
MoCA6.3 ± 6.212.2 ± 8.2−6.36<0.0010.98 (0.92–1.04)NS
CASI37.7 ± 23.658.6 ± 25.4−7.18<0.0010.99 (0.98–1.01)NS
NPI14.0 ± 11.85.4 ± 7.98.73<0.0011.05 (1.03–1.08)<0.001
UPDRS-M30.9 ± 19.918.2 ± 16.68.34<0.0011.02 (1.01–1.03)0.002
DLB features
Fluctuation56 (65.9)60 (10.3)159.11<0.00110.22 (5.76–18.13)<0.001
VH26 (30.6)30 (5.2)62.24<0.0014.18 (2.20–7.95)<0.001
Parkinsonism58 (68.2)148 (25.5)63.27<0.0014.68 (2.77–7.91)<0.001
RBD21 (24.7)56 (9.6)16.46<0.0012.84 (1.52–5.29)<0.001
DaTabN12 (63.2)20 (30.3)6.780.0091.16 (0.23–3.29)NS
History of CVA26 (30.6)128 (22.0)3.06NS1.11 (0.63–1.94)NS
Comparison of demographic and background characteristics between groups with FOSSQ + and FOSSQ – adjusted for age and disease severity according to CDR. Comparison of each cognitive domain in the CASI between the FOSSQ + and FOSSQ- groups before adjustment revealed that the FOSSQ + group had significantly lower scores in all domains (p < 0.001). After adjustment for age and disease severity, the FOSSQ + group had significantly lower scores only in the attention and language domains (Table 3).
TABLE 3

Comparison of each cognitive domain in CASI between groups with FOSSQ + and FOSSQ – adjusted for age, education, gender, and disease severity according to CDR.

Mean ± SD
Non-adjusted
Adjusted
FOSSQ +FOSSQ−tpOR (95% CI)p
N85581
RMM6.2 ± 3.38.1 ± 2.7−5.26<0.0010.98 (0.88–1.09)NS
RCM3.6 ± 3.25.9 ± 4.1−4.90<0.0011.01 (0.92–1.11)NS
ATT2.3 ± 2.15.0 ± 2.3−10.00<0.0010.67 (0.59–0.77)<0.001
MEN1.6 ± 2.64.0 ± 3.5−5.99<0.0010.85 (0.75–0.95)0.006
ORI7.4 ± 5.611.1 ± 5.9−5.54<0.0011.03 (0.96–1.10)NS
ABS2.8 ± 2.34.3 ± 2.4−5.47<0.0010.93 (0.86–1.15)NS
LAN5.8 ± 3.07.9 ± 2.2−7.52<0.0010.89 (0.80–0.99)0.044
DRAW4.5 ± 3.86.6 ± 4.0−4.60<0.0011.02 (0.94–1.10)NS
ANM3.6 ± 3.25.8 ± 3.5−5.58<0.0011.04 (0.93–1.15)NS
Comparison of each cognitive domain in CASI between groups with FOSSQ + and FOSSQ – adjusted for age, education, gender, and disease severity according to CDR. Comparison of frequency of symptom fluctuation in the MFCS and language symptoms in the HAICDDS-Language between FOSSQ + and FOSSQ- before and after adjustment for age and disease severity showed that FOSSQ + had a significantly higher frequency in all domains in the MFCS and HAICDDS-Language except for language impairment, which occurred much earlier than the other symptoms (HAICDDS-L7) (Table 4). Given our recent finding that HAICDDS-L8 has the highest power for discrimination of DLB when compared to other types of dementia (Lin et al., 2018), we further combined FOSSQ with HAICDDS-L8 and found that the positive rate for each question were DLB (61.9%), VaD (29.0%), AD (7.8%), and ND (2.6%).
TABLE 4

Comparison of frequency of fluctuation symptoms in MFCS and language symptoms in HAICDDS-Language between groups with FOSSQ + and FOSSQ – adjusted for age and disease severity according to CDR.

Mean ± SD
Non-adjusted
Adjusted
FOSSQ +FOSSQ −tpOR (95% CI)p
N85581
MFCS
Disorganized speech37 (43.5)34 (5.9)110.52<0.0015.74 (3.17–10.41)<0.001
Drowsy/lethargic57 (67.1)156 (26.9)55.11<0.0013.39 (1.99–5.77)<0.001
Sleep > 2 h63 (74.1)121 (20.8)105.32<0.0016.68 (3.77–11.82)<0.001
Staring into space57 (67.1)73 (12.6)140.17<0.0017.88 (4.41–14.08)<0.001
MFCS total score2.5 ± 1.20.7 ± 1.015.69<0.0013.12 (2.38–4.10)<0.001
HAICDDS-Language
L160 (70.6)173 (29.8)87.76<0.0013.09 (1.78–5.37)<0.001
L268 (80.0)199 (34.3)96.55<0.0013.01 (1.54–5.90)0.001
L354 (63.5)140 (24.1)91.10<0.0012.38 (1.35–4.19)0.003
L421 (24.7)22 (3.8)60.31<0.0014.70 (2.37–9.56)<0.001
L559 (69.4)155 (26.7)62.10<0.0012.65 (1.48–4.77)0.001
L661 (71.8)198 (34.1)74.68<0.0012.87 (1.66–4.96)<0.001
L72 (2.4)6 (1.0)0.89NS3.33 (0.56–19.64)NS
L828 (32.9)30 (5.2)71.97<0.0014.96 (2.62–9.38)<0.001
Language total score6.0 (3.2)1.9 (2.4)13.57<0.0011.45 (1.30–1.61)<0.001
Comparison of frequency of fluctuation symptoms in MFCS and language symptoms in HAICDDS-Language between groups with FOSSQ + and FOSSQ – adjusted for age and disease severity according to CDR.

Discussion

As a sub-study of the project HAICDDS, we analyzed data from a relatively large population (666 individuals) and obtained important results. First, we successfully demonstrated that even a single question could provide good discrimination among dementia stages and subtypes. The frequencies of FOSSQ + in patients with CDR scores of 0, 0.5, 1, 2, and 3 were 3.8, 3.0, 15.2, 26.1, and 43.5%, respectively, indicating that the frequency of FOS significantly increased with increase in dementia severity. Regarding discrimination of dementia subtypes, the FOS phenomenon was found more often in patients with DLB (54.0%) compared to those with either AD (6.1%) or VaD (18.0%). The frequency of FOSSQ + was lower among females, which is consistent with previous findings on freezing phenomenon in Parkinson’s disease (Park et al., 2014). Second, the frequency of FOS was not only highest in patients with DLB but was also more significantly associated with DLB features (p < 0.001), including cognitive fluctuations (OR = 10.22), visual hallucinations (OR = 4.18), parkinsonism (OR = 4.68), and REM sleep behavior disorder (OR = 2.84). Motor dysfunction according to the UPDRS-M is more severe in the FOSSQ + group (OR = 1.02; p = 0.002). Therefore, it is reasonable to consider FOS as part of the characteristic features in the diagnosis of DLB than that of ND or other types of dementia. The dopamine transporter imaging is not significantly different after adjustment, however. We proposed that non-DLB participants who performed dopamine transporter imaging were comorbid with motor dysfunction and were highly suspected to have parkinsonism. Hence, a relatively high percentage of DaTabN was found among these patients (47.1 and 20% in VaD and AD). Our next piece of research to address this issue and to clarify the association of FOS and dopamine transporter uptake in the striatal area is underway. Third, after adjustment for age and dementia severity, the FOSSQ + demonstrated a strong relationship with dysfunctions in attention, mental manipulation, and language domains in the CASI. This indicated that FOS might be a combination of these types of cognitive dysfunction, which is consistent with our hypothesis. Some researchers may argue that using the cognitive screening tool CASI, attention domain screens only registration and repetition and language domain screening cognitive performance on reading, writing, naming, and comprehension. Whether attention and language subscales in CASI represent the actual functions of attention and language might be controversial based only on a cognitive screening tool. Further detailed and specific neuropsychological tests to clarify the association of FOS with cognitive functions will be necessary. Fourth, it is consistent with our recent findings of language dysfunction being more severe in patients with DLB than those with other dementia using the HAICDDS-Language questionnaire (Lin et al., 2018). In the study, we found that the discriminative ability of the HAICDDS-Language, especially the HAICDDS-L8 (“Does his/her speech reduce pitch range and reduced volume?”) among patients with DLB/PDD and AD was robust (OR = 9.16; 95% CI: 6.33–13.25) (Lin et al., 2018). Therefore, in the current study, we combined the FOSSQ with HAICDDS-L8 and found an increase of positive rate in DLB (61.9%) which is much higher than those in VaD (29.0%), AD (7.8%), or ND (2.6%). Finally, in the HAICDDS project, we have continuously provided evidence that the combination of multiple standardized and structured questions is more powerful and can be optimized using artificial intelligence with machine learning techniques. This was the original idea behind the design of the HAICDDS questionnaire. This study has several limitations. First, we used a single questionnaire for detecting FOS in patients with DLB and other forms of dementia; therefore, further studies using more tools are required to confirm the findings. Second, we used the original Taiwanese version of the questionnaire, which, although we translated to English, would call for a more precise and colloquial translation. Third, our study was conducted in only three centers in Taiwan. Therefore, the findings on the prevalence and association factors of FOS are not generalizable to all patients with DLB or other types of dementia.

Conclusion

In conclusion, our study showed that the informant-based single questionnaire FOSSQ can be a practical screening tool for the discrimination of DLB from ND or other types of dementia. The FOSSQ can be applied in clinical practice as well as in the dementia registration platform. Further machine learning techniques using artificial intelligence could improve the accuracy and efficiency of the questionnaire.

Data Availability Statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation, to any qualified researcher.

Ethics Statement

The studies involving human participants were reviewed and approved by the Show Chwan Memorial Hospital. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

Author Contributions

P-YC undertook the literature search and data analysis, edited the Author Contributions, and was mainly responsible for revisions and drafts of the manuscript. M-CP participated in the data analysis and contributed to revisions and the final draft of the manuscript. G-UH undertook the literature search and contributed to revisions. C-YW contributed to revisions of the manuscript. R-CT undertook the literature search and contributed to revisions.

Conflict of Interest

P-YC work has been partly supported by the Show Chwan Memorial Hospital. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
  22 in total

1.  The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Guy M McKhann; David S Knopman; Howard Chertkow; Bradley T Hyman; Clifford R Jack; Claudia H Kawas; William E Klunk; Walter J Koroshetz; Jennifer J Manly; Richard Mayeux; Richard C Mohs; John C Morris; Martin N Rossor; Philip Scheltens; Maria C Carrillo; Bill Thies; Sandra Weintraub; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

2.  Cutoff scores of the cognitive abilities screening instrument, Chinese version in screening of dementia.

Authors:  Ker-Neng Lin; Pei-Ning Wang; Chia-Yih Liu; Wei-Ta Chen; Yi-Chung Lee; Hsiu-Chih Liu
Journal:  Dement Geriatr Cogn Disord       Date:  2002       Impact factor: 2.959

Review 3.  Freezing beyond gait in Parkinson's disease: a review of current neurobehavioral evidence.

Authors:  S Vercruysse; M Gilat; J M Shine; E Heremans; S Lewis; A Nieuwboer
Journal:  Neurosci Biobehav Rev       Date:  2014-04-23       Impact factor: 8.989

4.  Assessment of older people: self-maintaining and instrumental activities of daily living.

Authors:  M P Lawton; E M Brody
Journal:  Gerontologist       Date:  1969

Review 5.  Intellectual impairment in Parkinson's disease: clinical, pathologic, and biochemical correlates.

Authors:  J L Cummings
Journal:  J Geriatr Psychiatry Neurol       Date:  1988-01       Impact factor: 2.680

6.  Freezing phenomenon in patients with parkinsonian syndromes.

Authors:  N Giladi; R Kao; S Fahn
Journal:  Mov Disord       Date:  1997-05       Impact factor: 10.338

Review 7.  Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association.

Authors:  Philip B Gorelick; Angelo Scuteri; Sandra E Black; Charles Decarli; Steven M Greenberg; Costantino Iadecola; Lenore J Launer; Stephane Laurent; Oscar L Lopez; David Nyenhuis; Ronald C Petersen; Julie A Schneider; Christophe Tzourio; Donna K Arnett; David A Bennett; Helena C Chui; Randall T Higashida; Ruth Lindquist; Peter M Nilsson; Gustavo C Roman; Frank W Sellke; Sudha Seshadri
Journal:  Stroke       Date:  2011-07-21       Impact factor: 7.914

Review 8.  Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium.

Authors:  Ian G McKeith; Bradley F Boeve; Dennis W Dickson; Glenda Halliday; John-Paul Taylor; Daniel Weintraub; Dag Aarsland; James Galvin; Johannes Attems; Clive G Ballard; Ashley Bayston; Thomas G Beach; Frédéric Blanc; Nicolaas Bohnen; Laura Bonanni; Jose Bras; Patrik Brundin; David Burn; Alice Chen-Plotkin; John E Duda; Omar El-Agnaf; Howard Feldman; Tanis J Ferman; Dominic Ffytche; Hiroshige Fujishiro; Douglas Galasko; Jennifer G Goldman; Stephen N Gomperts; Neill R Graff-Radford; Lawrence S Honig; Alex Iranzo; Kejal Kantarci; Daniel Kaufer; Walter Kukull; Virginia M Y Lee; James B Leverenz; Simon Lewis; Carol Lippa; Angela Lunde; Mario Masellis; Eliezer Masliah; Pamela McLean; Brit Mollenhauer; Thomas J Montine; Emilio Moreno; Etsuro Mori; Melissa Murray; John T O'Brien; Sotoshi Orimo; Ronald B Postuma; Shankar Ramaswamy; Owen A Ross; David P Salmon; Andrew Singleton; Angela Taylor; Alan Thomas; Pietro Tiraboschi; Jon B Toledo; John Q Trojanowski; Debby Tsuang; Zuzana Walker; Masahito Yamada; Kenji Kosaka
Journal:  Neurology       Date:  2017-06-07       Impact factor: 9.910

Review 9.  Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium.

Authors:  I G McKeith; D W Dickson; J Lowe; M Emre; J T O'Brien; H Feldman; J Cummings; J E Duda; C Lippa; E K Perry; D Aarsland; H Arai; C G Ballard; B Boeve; D J Burn; D Costa; T Del Ser; B Dubois; D Galasko; S Gauthier; C G Goetz; E Gomez-Tortosa; G Halliday; L A Hansen; J Hardy; T Iwatsubo; R N Kalaria; D Kaufer; R A Kenny; A Korczyn; K Kosaka; V M Y Lee; A Lees; I Litvan; E Londos; O L Lopez; S Minoshima; Y Mizuno; J A Molina; E B Mukaetova-Ladinska; F Pasquier; R H Perry; J B Schulz; J Q Trojanowski; M Yamada
Journal:  Neurology       Date:  2005-10-19       Impact factor: 9.910

10.  The Language Profile of Behavioral Variant Frontotemporal Dementia.

Authors:  Chris J D Hardy; Aisling H Buckley; Laura E Downey; Manja Lehmann; Vitor C Zimmerer; Rosemary A Varley; Sebastian J Crutch; Jonathan D Rohrer; Elizabeth K Warrington; Jason D Warren
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

View more
  2 in total

1.  Synuclein Motor Dysfunction Composite Scale for the Discrimination of Dementia With Lewy Bodies From Alzheimer's Disease.

Authors:  Ying-Tsung Chen; Satoshi Orimo; Cheng-Yu Wei; Guang-Uei Hung; Shieh-Yueh Yang; Pai-Yi Chiu
Journal:  Front Aging Neurosci       Date:  2022-05-19       Impact factor: 5.702

2.  The challenges of COVID-19 for people with dementia with Lewy bodies and family caregivers.

Authors:  Alison Killen; Kirsty Olsen; Ian G McKeith; Alan J Thomas; John T O'Brien; Paul Donaghy; John-Paul Taylor
Journal:  Int J Geriatr Psychiatry       Date:  2020-08-18       Impact factor: 3.850

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.